Pfizer Inc
The American pharmaceutical and biotechnology corporation Pfizer was founded in 1849 by German immigrants Charles Pfizer and Charles F. Erhart and is headquartered in New York City. Pfizer develops, manufactures, and distributes vaccines and medicines for immunology, oncology, and neurology, among others.
Pfizer is traded on the New York Stock Exchange and employs over 75,000 employees.
Location: New York, NY, United States
Industry: Pharmaceuticals
Sector: Health Care / Life Sciences
CEO: Albert Bourla PhD, DVM
Valuation: $316 billion
Latest Pfizer Inc News and Updates
Pfizer to Acquire Cancer Treatment Company Seagen for $43 Billion
The acquisition of Seagen, which is expected to close later this year or in early 2024, adds it to a list of companies that Pfizer owns.
Moderna Is Suing Pfizer and BioNTech Over Patent Misuse
Moderna and Pfizer produced vaccines in record time to help people get inoculated against COVID-19. Why is Moderna suing Pfizer? Here's what we know.
When Will the Pfizer Lyme Disease Vaccine Be Here and Will It Work?
The world has a promising Lyme disease vaccine candidate courtesy of Pfizer Inc. (PFE) and its partner in the process, Valneva SE (VALN).
Pfizer to Acquire Global Blood Therapeutics, Achieves Long-Time Goal
Pfizer is acquiring Global Blood Therapeutics in a deal valued at $5.4 billion, which helps Pfizer realize its long-time goal of having a sickle-cell disease portfolio.
Explainer: Pfizer vs. Moderna COVID-19 Vaccines for Kids Under 5
Pfizer and Moderna both offer a COVID-19 vaccine for kids under five. Now, the FDA has approved both vaccines for children over six months of age.
Paxlovid May Be in Short Supply but That Could Soon Change
Pfizer's antiviral medication Paxlovid has been in short supply due to manufacturing time and other factors. However, the U.S. government is now working to change that.
How to Join Pfizer’s Omicron-Specific Vaccine Trial—1,400 Slots
Pfizer and BioNTech announced clinical trials for its omicron-specific COVID-19 vaccine. About 1,400 individuals are needed from unvaccinated to those who have received 2 or 3 doses.
Pfizer's Omicron Vaccine Should Be Available in March—Too Late?
Pfizer and Moderna are both working on a vaccine for the omicron variant of the COVID-19 virus. When will the vaccines be available? Will they be too late?
When Will Pfizer's COVID-19 Pill Be Available in Canada?
Pfizer’s antiviral COVID-19 pill, Paxlovid, got the green light in the U.S. for emergency use. When will Pfizer's COVID-19 pill be available in Canada?
Which Vaccines Are Effective Against Omicron? Pfizer and Moderna
As the omicron variant of the COVID-19 virus spreads across globe, people want to know more about the vaccines. Which vaccines are effective against omicron?
Arena Pharmaceuticals' Pipeline Includes Bowel Disease Treatments
With Pfizer poised to acquire Arena Pharmaceuticals, the drug company's pipeline comes into question. What's Arena developing?
Who Owns BioNTech and Does Ugur Sahin Have a Stake?
BioNTech has said that its vaccine works against the omicron variant. Who owns BioNTech and does Dr. Ugur Sahin have a stake in the company?
Will Pfizer’s COVID-19 Vaccine Protect Against the Omicron Variant?
Pfizer CEO Albert Bourla seems confident that the company's COVID-19 vaccine and antiviral medication will be effective at protecting against the omicron variant.
Pfizer CEO Wasn't Arrested by the FBI—How the Rumor Started
Pfizer CEO Albert Bourla wasn't arrested by FBI agents and he isn't facing criminal charges. How did the rumors start?
Pfizer's New COVID-19 Pill Plus HIV Drug Ritonavir Is 89% Effective Against Severe Illness
Pfizer's new pill to combat COVID-19 hospitalization is on its way. It is combined with ritonavir, an HIV treatment pill. So who makes ritonavir?
Only Certain People Are Eligible for Pfizer's COVID-19 Booster Shot
Those who are eligible for the Pfizer vaccine booster shot fall under specific groups deemed to be at higher risk of reinfection or server disease.
Who Is Exempt From COVID-19 Vaccine Mandate? Deadlines Approach
As deadlines approach for nearly 100 million Americans impacted by Biden's COVID-19 vaccine mandate, many people are scrambling to secure a religious exemption.
When Will COVID-19 Vaccine Boosters Be Available?
With conflicting advice about COVID-19 vaccine booster shots, when will they be available for Americans? What are the current recommendations?
How to Enroll a Child in a COVID-19 Vaccine Trial
Clinical trials for COVID-19 vaccine safety and effectiveness in children under 12 are ongoing. Demand for trial participation is high, so parents might need to be patient.
Pfizer Paid the Largest Criminal Fine in U.S. History—Lawsuit Details
GlaxoSmithKline might have settled the largest healthcare lawsuit in U.S. history, by Pfizer still holds the record for paying the largest criminal fine.
When Is Pfizer Booster Available? Fauci Gives COVID-19 Booster Update
When is the Pfizer booster available? See what Dr. Anthony Fauci said about the rollout of both the Pfizer and Moderna boosters.
Bill Gates Is an Advocate for COVID Vaccines, Doesn't Own Pfizer
After news that Pfizer’s COVID-19 vaccine received full approval from the FDA, rumors circulated that Bill Gates might stand to profit. Is he involved with Pfizer?
What Does Full FDA Approval Mean for Vaccines?
The Pfizer-BioNTech COVID-19 vaccine has been officially granted full FDA approval. How will that change the vaccine landscape?
Is TRIL a Buy After Pfizer Acquires Trillium Therapeutics?
Pfizer is buying out the remainder of Trillium Therapeutics in a multi-billion-dollar deal. Should investors buy TRIL stock? Here's what investors can expect.
Is Pfizer’s COVID-19 Vaccine Safe and Effective?
There were a total of six deaths in the late-stage clinical trial for Pfizer’s COVID-19 vaccine. So, is Pfizer’s COVID-19 vaccine safe and effective?
Major Developments for Johnson & Johnson in 3Q16
Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]
Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15
Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.
How Spark Therapeutics Is Positioned in 2018
Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.
Merck Expects Modest Revenue Growth in Fiscal 2016
Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.
Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success
On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.
Expanding Service Sector Gives Relief to Economy in September
With manufacturing slowing, a reading of the Non-Manufacturing Index at an above-neutral level (56.9) may provide some relief to the US economy, which is highly dependent on the service sector for its economic growth.
Where Is Pfizer's COVID-19 Vaccine Being Made?
There's a lot of interest in COVID-19 vaccines. Where is Pfizer's COVID-19 vaccine being made? When will the vaccine be authorized and available?
How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.
What’s the Story behind the Pfizer-Medivation Deal?
Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.
Why Eylea Could Face Tough Competition in 2016
In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.
A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta
In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.
Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15
Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.
Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?
Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.
Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer
Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.
Understanding Bristol-Myers Squibb’s Other Segments
Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.
Teva’s Granix Gets FDA Approval for Expanded Indication
Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.
GlaxoSmithKline Increases Top Line in 2Q16
GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.
How to Invest in Global Wide Moat Stocks
The Morningstar Global Wide Moat Focus Index has global exposure, unlike the Morningstar International Moat Index (MOTI).
What Are Generic Drugs and Why Are They Important?
TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]
The Pharmacyclics–AbbVie Merger: The Basics of AbbVie
A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.
Non-Opioid Pain Therapy Market Opportunity for Teva
The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.
Buy Allows Horizon to Further Expand into Orphan Drug Space
Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.
Humira May Continue to Drive AbbVie’s Revenue Growth
In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Pfizer Has Strong Track Record since 2010
As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.
